102419Development of USP7 inhibitors for cancer therapyClosedCollaborative R&DInnovate UKMISSION Therapeutics, a UK-based SME is a world-leading expert in deubiquitylating enzyme (DUB) drug discovery, with a number of projects in lead optimisation. Through counter-screening our ongoing projects, we identified a small molecule inhibtiors of a DUB drug target with potential to be developed for treating soft tissue sarcomas and other cancers with clear unmet need and significant market potential. In this project we aim to pursue and develop these inhibitors with the overall objective of producing first-in-class DUB inhibitors as treatments for some of the most difficult to treat cancers.